8-K: ALX Oncology Holdings Inc. Share Exchange Agreement

ALX Oncology Holdings Inc. has entered into exchange agreements with certain stockholders to surrender shares for pre-funded warrants, settling on October 15, 2026.

Summary

• ALX Oncology Holdings Inc. (the Company) entered into private exchange agreements on October 14, 2026, with specific stockholders.
• Under these agreements, stockholders will surrender a total of 13,353,384 shares of common stock.
• In return, the Company will issue pre-funded warrants to purchase an equivalent number of shares of common stock.
• The exchange involves funds affiliated with Blackstone Annex Master Fund L.P., RA Capital Healthcare Fund, L.P., and venBio Global Strategic Fund, L.P.
• The transaction is being conducted under an exemption from registration pursuant to Section 3(a)(9) of the Securities Act of 1933.
• The exchange is expected to settle on or about October 15, 2026.
• Each pre-funded warrant has an exercise price of $0.001 per share and is exercisable until fully exercised, subject to ownership limitations.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative development, as it involves a significant exchange of existing shares for pre-funded warrants, indicating a potential need for capital or a restructuring of ownership without immediate new capital infusion.

Positives

• The exchange provides a mechanism for certain stockholders to convert their common stock into pre-funded warrants, potentially offering flexibility.
• The transaction is structured to comply with securities regulations via Section 3(a)(9) exemption.

Negatives

• The exchange involves a significant number of shares (13,353,384) being surrendered, which could indicate a need for liquidity or a restructuring of the shareholder base.
• Issuing pre-funded warrants rather than direct capital may suggest the company is not raising new funds at this time, or that the warrant holders are seeking a different form of investment.
• The ownership limitations (4.99% or 9.99%, potentially up to 19.99%) on warrant exercise could complicate future strategic moves for the warrant holders.

Risks

• Potential for increased dilution if warrants are exercised, although pre-funded warrants imply immediate conversion of equity.
• The ownership limitations on warrant exercise could lead to complex adjustments and potential disputes.
• The reliance on Section 3(a)(9) exemption suggests the transaction is between the company and existing security holders, not a broad public offering.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding future financial performance. The primary focus is on the details of the share exchange agreement.

Management Comments

• The Company entered into separate privately-negotiated exchange agreements with certain stockholders.
• The Stockholders agreed to surrender an aggregate of 13,353,384 shares of the Company's common stock.
• The Company agreed to issue to the Stockholders pre-funded warrants to purchase an aggregate of 13,353,384 shares of Common Stock.

Industry Context

StockSavvy.ai notes that such exchange agreements for pre-funded warrants are often utilized by companies, particularly in the biotech and pharma sectors, to manage shareholder structures or facilitate specific investor needs without immediately diluting the market with new share issuances. This can be a tool for strategic investors or to manage existing debt/equity structures.

Stakeholder Impact

• Shareholders: The exchange impacts the ownership structure by converting common stock into pre-funded warrants for specific holders, potentially altering voting power and future equity stakes.
• Company: The company issues pre-funded warrants, which represent a commitment to issue shares upon exercise, impacting its capital structure and potential future dilution.

Next Steps

• Settlement of the exchange agreements on or about October 15, 2026.
• Potential exercise of pre-funded warrants by holders, subject to ownership limitations.

Key Dates

Keywords

Exchange Agreement, Pre-funded Warrants, Common Stock, Securities Act, Stockholder, Blackstone, RA Capital, venBio